论文部分内容阅读
目的通过对胃癌患者手术治疗前后CA19.9、高敏C反应蛋白(hs-CRP)的检测分析,探讨提高胃癌诊断水平和预后措施的新方法。方法采用电化学发光法检测胃癌患者手术治疗前后血清CA19.9的水平、免疫比浊法检测其血清hs-CRP的含量,同时建立健康对照组进行比较。结果手术前CA19.9含量为(88.6±52.4)U/ml,hs-CRP含量为(36.5±16.1)mg/L,均显著高于健康对照组,差异有统计学意义(P<0.01)。手术前后两指标含量差异有统计学意义(P<0.01)。结论 CA19.9与hs-CRP的联合检测对胃癌手术患者的预后评估及进一步指导治疗具有很好的临床指导价值,可提高对肿瘤复发的预见能力。
Objective To explore the method of improving the diagnosis and prognosis of gastric cancer by detecting and analyzing the levels of CA19.9 and hs-CRP in patients with gastric cancer before and after operation. Methods The level of serum CA19.9 in patients with gastric cancer before and after operation was detected by electrochemiluminescence method. The content of hs-CRP in serum was detected by immunoturbidimetry. At the same time, the healthy control group was established for comparison. Results The level of CA19.9 before surgery was (88.6 ± 52.4) U / ml and the content of hs-CRP was (36.5 ± 16.1) mg / L, both of which were significantly higher than those of healthy controls (P <0.01). The content of the two indexes before and after surgery had statistical significance (P <0.01). Conclusion The combined detection of CA19.9 and hs-CRP has a good clinical value in prognosis evaluation and further treatment of gastric cancer patients, which can improve the predictive ability of tumor recurrence.